ENDRA Life Sciences (NDRA) Price & Analysis

Compare

852 Followers

NDRA Stock Chart & Stats

$5.16

-$0.12(-1.95%)

At close: Jan 08 4:00 PM EST

$5.16

-$0.12(-1.95%)

Day’s Range― - ―

52-Week Range$2.90 - $11.96

Previous CloseN/A

Volume13.45K

Average Volume (3M)514.97K

Market Cap

$6.02M

Enterprise Value$1.27M

Total Cash (Recent Filing)$794.04K

Total Debt (Recent Filing)$525.33K

Price to Earnings (P/E)―

Beta1.23

Next Earnings

Mar 26, 2026

EPS Estimate

-1.23

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.10

Shares Outstanding1,166,441

10 Day Avg. Volume1,472,495

30 Day Avg. Volume514,968

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)2.74

Price to Sales (P/S)0.00

P/FCF Ratio-0.95

Enterprise Value/Market Cap0.21

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-7.71

Enterprise Value/Ebitda-0.16

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusModerate Buy

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Market OpportunityThe launch of the TAEUS application for early detection of Steatotic Liver Disease opens a large market opportunity.

Product DevelopmentENDRA's TAEUS platform offers a cost-effective alternative to CT and MRI, enabling new ways to visualize human tissue composition at the point-of-care.

Bears Say

Price TargetThe 12-month price target for ENDRA has been lowered from $50 to $46, despite maintaining a BUY rating.

Revenue GenerationENDRA is a late stage medical device development/early stage commercialization company so it generates no revenues.

ENDRA Life Sciences News

Endra Life Sciences announces results from Taeus Liver device feasibility study

Endra Life Sciences (NDRA) announced new results from its 2025 Taeus Liver device feasibility study demonstrating that Taeus’...

19d ago

NDRA

Endra Life Sciences (NDRA) Q3 Earnings Cheat Sheet

Endra Life Sciences (NDRA) is scheduled to report 3rd quarter earnings on 11/17/2025. Regarding Q3 estimates, Wall Street...

1M ago

NDRA

ENDRA Life Sciences Reports Q3 2025 Financial Results

Endra Life Sciences ( ($NDRA) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

NDRA

ENDRA Life Sciences Granted Nasdaq Compliance Extension

ENDRA Life Sciences ( ($NDRA) ) just unveiled an announcement. On October 31, 2025, ENDRA Life Sciences received...

1M ago

NDRA

Endra Life Sciences commences staking of HYPE digital asset holdings

ENDRA Life Sciences (NDRA) announced it has commenced staking its holdings of HYPE (HYPE-USD), the native token of...

1M ago

NDRA

Endra Life Sciences files to sell 2.68M shares of common stock for holders

The company will not receive any proceeds from the sale of shares by the selling stockholders. Published first...

2M ago

NDRA

ENDRA Life Sciences Signs Sales Agreement with Lucid

An announcement from ENDRA Life Sciences ( ($NDRA) ) is now available. On October 29, 2025, ENDRA Life...

2M ago

NDRA

Endra Life Sciences reports Q2 EPS ($1.71) vs. (8c) last year

As of June 30, 2025, ENDRA reported $1.8 million in cash and cash equivalents, providing resources to execute...

4M ago

NDRA

ENDRA Life Sciences Forms Cryptocurrency Advisory Board

An announcement from ENDRA Life Sciences ( ($NDRA) ) is now available. ENDRA Life Sciences Inc. has initiated...

5M ago

NDRA

Endra Life Sciences files to sell 15.7M shares of common stock

Lucid Capital Markets acted as sole book running manager for the offering. Published first on TheFly – the...

6M ago

NDRA

ENDRA Life Sciences Unveils New Business Strategy

ENDRA Life Sciences ( ($NDRA) ) has issued an announcement. On June 11, 2025, ENDRA Life Sciences Inc....

6M ago

NDRA

ENDRA Life Sciences Faces Nasdaq Compliance Challenge

ENDRA Life Sciences ( ($NDRA) ) has provided an announcement. On May 27, 2025, ENDRA Life Sciences received...

7M ago

NDRA

ENDRA Life Sciences: Strategic Shift and Financial Update

Endra Life Sciences ( ($NDRA) ) has released its Q1 earnings. Here is a breakdown of the information...

7M ago

NDRA

Endra Life Sciences reports Q1 EPS ($1.86) vs ($449.58) last year

“Obesity, type 2 diabetes and other metabolic diseases are among the most pressing health challenges today, adding in...

7M ago

NDRA

NDRA FAQ

What was ENDRA Life Sciences Inc’s price range in the past 12 months?

ENDRA Life Sciences Inc lowest stock price was $2.90 and its highest was $11.96 in the past 12 months.

What is ENDRA Life Sciences Inc’s market cap?

ENDRA Life Sciences Inc’s market cap is $6.02M.

When is ENDRA Life Sciences Inc’s upcoming earnings report date?

ENDRA Life Sciences Inc’s upcoming earnings report date is Mar 26, 2026 which is in 93 days.

How were ENDRA Life Sciences Inc’s earnings last quarter?

ENDRA Life Sciences Inc released its earnings results on Nov 17, 2025. The company reported -$2.1 earnings per share for the quarter, missing the consensus estimate of -$1.95 by -$0.15.

Is ENDRA Life Sciences Inc overvalued?

According to Wall Street analysts ENDRA Life Sciences Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does ENDRA Life Sciences Inc pay dividends?

ENDRA Life Sciences Inc does not currently pay dividends.

What is ENDRA Life Sciences Inc’s EPS estimate?

ENDRA Life Sciences Inc’s EPS estimate is -1.23.

How many shares outstanding does ENDRA Life Sciences Inc have?

ENDRA Life Sciences Inc has 1,166,441 shares outstanding.

What happened to ENDRA Life Sciences Inc’s price movement after its last earnings report?

ENDRA Life Sciences Inc reported an EPS of -$2.1 in its last earnings report, missing expectations of -$1.95. Following the earnings report the stock price went up 7.903%.

Which hedge fund is a major shareholder of ENDRA Life Sciences Inc?

Currently, no hedge funds are holding shares in NDRA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

ENDRA Life Sciences Inc

ENDRA Life Sciences (NDRA) is a medical technology company that operates in the healthcare sector. The company is focused on developing innovative diagnostic tools, particularly in the field of liver disease. ENDRA's flagship product is the Thermo Acoustic Enhanced Ultrasound (TAEUS) system, which aims to provide a cost-effective and non-invasive solution for assessing liver fat content, aiding in the management of conditions such as non-alcoholic fatty liver disease (NAFLD). The TAEUS system is designed to work alongside standard ultrasound systems, enhancing their capabilities with ENDRA's proprietary technology.